| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 118 | 898 | 13.661 | 19.041 | 22.976 | 23.416 | 30.276 | 35.169 | 34.934 |
| Total Income - EUR | - | 118 | 898 | 13.661 | 19.041 | 22.976 | 23.417 | 30.276 | 35.172 | 34.935 |
| Total Expenses - EUR | - | 479 | 1.306 | 9.088 | 22.161 | 22.773 | 21.672 | 22.872 | 24.967 | 30.906 |
| Gross Profit/Loss - EUR | - | -361 | -409 | 4.573 | -3.120 | 203 | 1.745 | 7.403 | 10.205 | 4.029 |
| Net Profit/Loss - EUR | - | -365 | -435 | 4.163 | -3.691 | -434 | 1.057 | 6.513 | 9.896 | 2.981 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Neurogenica Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 22.949 | 15.760 | 9.341 | 2.691 | 1.143 | 1.930 |
| Current Assets | - | 163 | 45 | 6.394 | 10.484 | 10.903 | 7.513 | 13.805 | 14.732 | 21.952 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 27 | 1.335 | 1.368 | 1.973 | 1.445 | 3.046 | 2.490 | 13 |
| Cash | - | 163 | 17 | 5.059 | 9.116 | 8.929 | 6.068 | 10.759 | 12.242 | 21.939 |
| Shareholders Funds | - | -320 | -750 | 3.427 | -331 | -759 | 315 | 6.818 | 13.256 | 7.116 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 483 | 795 | 2.967 | 33.764 | 27.421 | 16.540 | 9.679 | 2.618 | 16.766 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neurogenica Srl